Tulane University research shows that a cancer drug, BLZ945, can significantly decrease HIV levels in the brain by targeting infected cells, offering a new potential strategy to combat persistent HIV reservoirs.
The drug may eliminate the virus from concealed regions in the brain by focusing on infected cells, addressing a significant hurdle in HIV treatment.
According to a new study by Tulane University, an experimental drug initially developed for cancer treatment may help clear HIV from infected cells in the brain.
For the first time, researchers at Tulane National Primate Research Center found that a cancer drug significantly reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain by targeting and depleting certain immune cells that harbor the DOI: 10.1093/brain/awae153
This research was funded by the
/https://tf-cmsv2-smithsonianmag-media.s3.amazonaws.com/filer_public/d1/82/d18228f6-d319-4525-bb18-78b829f0791f/mammalevolution_web.jpg "How to Make a Mammal in Nine Evolutionary Steps")
Discussion about this post